North Bristol NHS Trust Strategy

Our new Trust strategy launched in February 2023. An overview can be seen in the plan on a page image to the right.

Our reason for existing as an organisation is to put the patient first by delivering outstanding patient experience– and that’s the focal point of our strategy, Our Aim. 

How we deliver that is so important and the NBT Cares ‘Values and Positive Behaviours Framework’ which we launched in Autumn 2022 underpin this.

Through our NBT Cares ‘Values and Positive Behaviours’ we are committed to being:

• Caring.
• Ambitious.
• Respectful, and
• Supportive.

We will continue to maintain overall focus on our three Trust objectives:

• Delivering great care.
• Healthcare for the future, and.
• Being an anchor in the community.

To support us to achieve our three Trust Objectives, we have new Improvement Priorities, which have the potential to transform what we do as a Trust on behalf of our patients.

Our Improvement Priorities which will help us to deliver our ultimate aim of delivering outstanding patient experience are:

1. high quality care – we’ll make our care better by design.
2. innovate to improve – we’ll unlock a better future.
3. people – our people will be proud to belong here.
4. sustainability – we’ll make best use of limited resources.
5. commitment to our community – we’ll be in our community, for our community.

Our Clinical Strategy

Our Joint Clinical Strategy

Our Patient Experience and Carer Strategy

Easy Read version:

Our Clinical Research Strategy

Clinical Research Strategy 2022-27.

Our Digital Vision

Our Patient Safety Strategy

Our People Strategy

Risk Management Strategy and Policy

Our Mental Health Strategy

Healthier Together

Healthier Together is the name given to our Bristol, North Somerset and South Gloucestershire Integrated Care System.

The Bristol, North Somerset and South Gloucestershire (BNSSG) Integrated Care Board (ICB) was established on 1 July 2022. We’re responsible for developing plans to meet the health needs of our population, managing the NHS budget and arranging for the provision of health services in our area.

Our work is focused on four key aims:

• Improving outcomes in population health and healthcare.
• Tackling inequalities in outcome, experience and access.
• Enhancing productivity and value for money.
• Helping the NHS support broader social and economic development.

The Annual Review for 2022 to 2023 can be viewed on the BNSSG website.

Sunflower Lanyard scheme

North Bristol NHS Trust is now proudly participating in the Hidden Disabilities Sunflower Lanyard scheme.

This means that those with a hidden disability can wear a sunflower lanyard or wristband to make their disability visible to those around them while in hospital. Staff should help you with any support or adjustments you may need.

You can find lanyards and wristbands in the main receptions of the Brunel building at Southmead Hospital and of Cossham Hospital.

What are hidden disabilities?

Some disabilities don’t have physical signs so we cannot always tell if someone has one. Hidden disabilities include autism, mental health, acquired/traumatic brain injury, sensory processing, multiple sclerosis, epilepsy, partial sight and hearing loss.

For instance, those with autism may need some extra time and space to process what is around them. People with partial sight may need help reading signs and other information.

You can learn more on the Hidden Disabilities website.

​What if I have additional needs?

The Learning Disabilities team are taking extra care of patients with additional need. Carers can also complete a COVID Passport for the patient.

The Sunflower scheme at NBT was kindly provided for by donations to Southmead Hospital Charity. 

This accessibility statement applies to the NHS website for North Bristol NHS Trust, www.nbt.nhs.uk. 

This website is run by North Bristol NHS Trust. We want as many people as possible to be able to use the website. For example, that means you should be able to:

• Use your web browser to change colours, contrast levels and fonts.
• Zoom in up to 400% without the text spilling off the screen.
• Navigate most of the website using just a keyboard.
• Navigate most of the website using speech recognition software.
• Listen to most of the website using a screen reader (including the most recent versions of JAWS (Job Access With Speech), NVDA (NonVisual Desktop Access) and VoiceOver.
• Access the website using a mobile or tablet.

AbilityNet has advice on making your device easier to use if you have a disability.

How accessible this website is

We know from our most recent accessibility audit that some parts/contents of this website are not fully accessible.

• Some PDF documents are not fully accessible.
• Some live video streams and videos do not have captions/subtitles.
• Some of our online forms are difficult to navigate using just a keyboard.
• Some images do not have text alternatives.

Feedback and contact information

If you have an accessibility query including:

• If you have any problems accessing information or using this website
• If you have any positive feedback about this website's accessibility

Please contact NBTCommunications@nbt.nhs.uk. We’ll consider your request and get back to you in 10 days.

Reporting accessibility problems with this website

We’re always looking to improve the accessibility of this website. If you find any problems not listed on this page or think we’re not meeting accessibility requirements, contact NBTCommunications@nbt.nhs.uk with details of the problem you have encountered.

Enforcement procedure

The Equality and Human Rights Commission (EHRC) is responsible for enforcing the Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018 (the ‘accessibility regulations’). If you’re not happy with how we respond to your complaint, contact the Equality Advisory and Support Service (EASS).

Contacting us by phone or visiting us in person

We want to ensure we can communicate effectively and provide you with information you can understand.

We can arrange for in-person support such as British Sign Language (BSL) interpreters or volunteer sighted guides.

Where possible, we can ensure communication support such as audio induction loops, quiet waiting spaces, longer appointment times etc. We can also provide information in different formats such as Easy Read and we can contact you in your preferred way, for example by phone, email, or letter.

You can contact us via a British Sign Language (BSL) interpreter using Sign Live, or please phone or email the contact details on your appointment letter.

Find out how to contact us.

Technical information about this website’s accessibility

North Bristol NHS Trust is committed to making this website (www.nbt.nhs.uk) accessible, in accordance with the Public Sector Bodies (Websites and Mobile Applications) (No. 2) Accessibility Regulations 2018.

Compliance status

This website is partially compliant with the Web Content Accessibility Guidelines version 2.1 AA standard, due to the non-compliances and exemptions listed below.

Non-accessible content

The content listed below is non-accessible for the following reasons.

Non-compliance with the accessibility regulations

PDFs and other documents

Many of our PDFs and Word documents are essential to providing our services and/or we have a legal and statutory obligation and legitimate business need to publish them. Examples include:

• Statutory and mandatory reports, including third party reports e.g. Auditors Report.
• Trust Board Papers and Integrated Performance Reports.
• Information specifically for clinicians e.g. care pathways and referral criteria.
• The structure of the content is not always available to assistive technology, which makes the content difficult to understand and navigate for users of screen readers (WCAG 2.1 success criterion Info and relationships 1.3.1).
• The reading order of the content is not always logical, which means some content does not make sense when read out by text-to-speech software (WCAG 2.1 success criterion Meaningful sequence 1.3.2).
• Images do not always have text alternatives, which means some content is not available when using text-to-speech software (WCAG 2.1 success criterion Text alternatives 1.1.1).

We are actively working to address accessibility issues and plan to either fix these or, where possible, replace them with accessible HTML pages.

Video content

Some of our videos do not meet accessibility standards because they do not have captions.
We are actively working to add captions/subtitles starting with the most popular videos published after 23 September 2020.

• Videos do not have transcripts or captions (WCAG 2.1 success criterion Audio-only and Video-only (Pre-recorded) 1.2.1, 1.2.2 and 1.2.3).

Images

Some images do not have a text alternative, so people using a screen reader cannot access the information. We are in the process of adding text alternatives for all images. When we publish new content, we’ll make sure our use of images meets accessibility standards.

• Text alternatives (WCAG 2.1 success criterion Text alternatives 1.1.1).

Other parts of the website that are not fully accessible

These include:

• Links to third party websites or software that we do not own or manage therefore cannot guarantee their accessibility, however, we are actively working with relevant partners to address these issues.

Content that’s not within the scope of the accessibility regulations

• Documents e.g. PDFs, published before 23 September 2018 that are not essential to providing our services.
• Captions on videos published before 23 September 2020.
• Site maps, however essential information i.e. address, has been provided.

If there is a specific document that you would like to request in an HTML format, we will do our best to oblige where possible and practicable. Please contact NBTCommunications@nbt.nhs.uk.

What we’re doing to improve accessibility

We are making sure that the accessibility issues highlighted in our recent audit and outlined in this statement are being prioritised and fixed. Measures include:

• Reviewing content for plain English.
• Updating all PDFs to be accessible using Acrobat Pro accessibility checker.
• There are a number of PDFs that do not meet accessibility guidelines. Consequently, as part of our work to improve the accessibility of this website, we are reviewing our use of PDFs.
• Adopt a principle to move away, where possible, from new content being produced in PDF format.
• Plans to remove or replace all older PDFs with more accessible content.
• Adding captions to videos published after 23 September 2020.
• Ongoing improvement to the design/usability of the website focusing on accessibility.
• Prioritising accessibility remedial work in all new development and improvement projects.
• Working with third party suppliers and partners to improve the accessibility of their products.

Preparation of this accessibility statement

This statement was prepared on 24 August 2020. It was last reviewed on 24 July 2023. It was last updated 4 August 2023. 

This website was last tested in July 2023 and testing is ongoing. The test was carried out using Silktide, with support from Redder LTD and NBT Communications.

Genomic vocabulary is vast and forever adapting and changing to keep up with advancements in the field.   

• In order to keep  your Genomic literacy and understanding up to date SWGLH recommend the Health Education England Genomics Education Programme Genomics' Glossary
• To make further suggestions for the list contact the Genomics Education Programme Team

Joel's Story

Joel Calvert, 32, signed up to the 100,000 genomes programme through the West of England Genomic Medicine Centre (WEGMC) in 2017 after it was suggested to him by his clinician at University Hospitals Bristol NHS Foundation Trust (UH Bristol). As a result of his participation in this pioneering programme, Joel was given answers about his condition that, until then, doctors and medical professionals had been unable to provide.

The results from his genetic testing showed that he had Meester-Loeys syndrome, a rare hereditary disorder which affects the connective tissue in those affected. Connective tissue provides strength and flexibility to structures such as bones, ligaments, muscles, and blood vessels and, as such, people with Meester-Loeys syndrome can often have a range of skeletal problems especially with bone structure. Joints can be rigid, with mild deformities in the digits and long bones and in the hip joint. However, the most serious problem can be an abnormal aorta which is at higher risk of enlargement and rupture.  This, however, does not appear in all patients but when it occurs it requires immediate lifesaving intervention. There are also several other genetic conditions which can affect the aorta in this way, some of which also have similar impact to joints and the skeleton.

Speaking about his condition and his experience, Joel said:“I’ve had this condition since I was born but due to the varied symptoms and the rarity of the condition, I wasn’t able to get a diagnosis until I took part in this project. The symptoms I showed varied across time; I was born with bilateral club feet and was consistently in plaster until I was a teenager. I also had contracture in ligaments in some of my fingers, mild scoliosis of the spine, and from around six years ago, chronic back pain.“I have seen a number of GPs and specialists over the years to try and treat the symptoms, and get a diagnosis. Unfortunately though, this was unsuccessful. “This was incredibly disheartening and, at times, frustrating. We tried a number of different treatments but without a named condition, it was harder to explain what was going on, and a lot of time was spent with the process of elimination. At a couple of points, I became so frustrated that I just stopped going to the GP as I felt that there wasn’t anything that could be done.

“After I agreed to take part in the 100,000 genomes programme, they took blood samples from myself and from members of my family and, earlier this year, I was contacted by Dr Karen Low at UH Bristol who confirmed I had Meester-Loeys Syndrome. Being able to finally get a diagnosis for the underlying condition is significant both in terms of how I manage the condition, but also for me personally. “Knowing what this condition is allows my doctors and me to have a more focused approach, and means we can try and manage my symptoms with a better understanding of the underlying cause. It also means I can have more of an idea about what to expect as I get older and there are steps that we can take now to address these issues earlier. Also, as it is hereditary, I can know what to expect if I have children, and will be able to discuss this with doctors and specialists in the future.

“It is also very liberating for me personally. When there was no diagnosis and no named cause of my symptoms, there were times when I doubted myself and the severity of my condition, and questioned whether I was wasting the time of my doctors. This is not a nice position to be in, but now that I know there is an underlying cause, it has provided peace of mind and reassurance that my concerns were valid.  

“Taking part in the 100,000 genomes programme has been massively significant for me. If it wasn’t for the wider work taking place as part of this initiative, I still wouldn’t have that clarity about my own condition. Beyond myself though, there are other people out there with this condition. Hopefully this programme may help lead to faster diagnosis people with Meester-Loeys syndrome and other similar conditions in the future.”

 

Libby's Story

A mother whose daughter died from cancer after treatment at the Royal United Hospital (RUH) in Bath has spoken about the value of joining the 100,000 Genomes Project for research and for helping her to come to terms with her grief.

Diane Woodland’s daughter Libby volunteered for the project after she was admitted to the RUH and diagnosed with a rare cancer. She died aged 25 in August 2018.

Diane said: “The doctors told us they’d never seen a cancer before like the one Libby had and they didn’t know what treatment to give her. “My deepest fear was that, having produced Libby and her brother George, it was something my husband and I had passed on to her.”

Tracie Miles, RUH gynaecology clinical nurse specialist for gynaecology cancer and legacy genomics practitioner, recruited Libby to the 100,000 Genomes Project through the West of England Genomic Medicine Centre (WEGMC) while she was being treated at the hospital. The national project was a major NHS initiative to sequence 100,000 genomes from patients with rare inherited diseases or with cancer and to transform NHS services to include genome sequencing as standard care for future patients. The ambitious aim to sequence 100,000 genomes (DNA sequences) from NHS patients was reached in December 2018.

Tracie said: “Libby wanted to know about her cancer. Her biggest fears were for her family and their future – she wanted more information for herself and for them. In addition she wanted to help patients in the future with information from her stored genomic data. The results that came back showed there was no inherited reason for her succumbing to this cancer. This was a real relief for her mum and her dad.”

Diane said: “It was just amazing to find out that George is very unlikely to have it, I can’t express how much that means.“Signing up for the trial means that, hopefully, things will be discovered that go on to help other people, which is what Libby so wanted to do from such an early age. It might take five or 15 years but I just hope that the information that’s needed is supplied – and I’m so proud and lucky that my daughter has been able to take part in this research.”

Tracie added said: “Genomics has the ability to influence the care we give today. For example a woman newly diagnosed with ovarian cancer will have her tumour tested to see if she carries an alteration of her BRCA 1 or 2 gene.  If that’s the case it may mean that her oncologist, the doctor who prescribes her chemotherapy, could have other therapeutic choices for her, and it may increase her survival advantage. It will also give important health information for her family, who may choose to be tested to see if they carry the altered gene, enabling them to access relevant screening and other cancer risk reducing strategies. So, the learning is already making a difference now for patients, not just in the future.”

The current focus for the local WEGMC teams is on returning results to patients and their families, where appropriate, and also sharing the important impact that this project, and genomic medicine in general, will have on future patients locally, nationally and potentially across the world.

Diane kindly agreed to share her story and that of her daughter Libby through a video which can be viewed here. 

The WE GMC team wanted to express our upmost thanks to Diane for taking the time and the courage to share this extremely personal experience and sharing her view of the importance of being involved in projects such as the 100,000 Genomes Project.
 

 

NHS England began a major reorganisation of the genetic laboratory network in England in 2018 with the aim of improving genomic testing in the NHS through standardisation, increasing capacity, acceleration of uptake of new technologies and by improving equity of patient access.

 

• All English Genomic laboratory services are now consolidated into a network of seven Genomic Laboratory Hubs (GLH) each hosted by an acute NHS Trust.

 

• The GLHs provide core rare disease and cancer genomic testing services for NHS patients in their geographical region. GLHs also provide specialist rare disease and cancer genomic testing for more than one region according to their areas of expertise.

 

This page was last updated 20:19 Tuesday 8th March 2022

12 & 13 November 2022

This virtual Certification in Urodynamics Course is to be run in collaboration with The Prometheus Group LATAM and the Bristol Urological Institute (BUI). It is an online course specifically for specialists in North and South America.

The course will be taught in both English and Spanish and aimed at doctors, nurses, clinical scientists and all allied-healthcare professionals who are already have some knowledge of urodynamics and not for those with no experience. The course finishes with a multiple choice quiz. Those who achieve satisfactory marks will be awarded the Certificate in Urodynamics. Those who do not pass are awarded a Certificate of Attendance. 

Course Director: Hashim Hashim, Consultant Urological Surgeon, Honorary Professor of Urology & Director of the Urodynamics Unit, Bristol Urological Institute

Faculty: 
Arturo Garcia, Consultant Urological Surgeon. Mexico
Andrew Gammie, Clinical Scientist, Bristol Urological Institute

Cost: US$850

To register your interest send an email directly to The Prometheus Group: dilucca.tpglatam@gmail.com

 

Workforce Development Partner Organisations

The delivery of the genomic medicine service workforce development strategy and it's compenent education and training plan is reliant on the collaboration of many individuals and teams across a network of organisations. 

The SWGLH team collaborates with:

NHSE/I Genomics Unit
HEE Genomics Education Programme
HEE SW Office Genomics lead
AHSNs - SWAHSN and WEAHSN
HEI’s - Plymouth, Exeter, Bristol, Bath, UWE and Gloucestershire
WFDL in acute trusts
CCG leads for Primary Care

Representatives from some of these organisations are members of the SWGMS partnership board